Institutional implant failure forecasting. Audit settlement values for BIA-ALCL, Allergan recall, and autoimmune-BII protocols.
MDL 2921
Mass Tort Sync Active
| Condition | Settlement |
|---|---|
| BIA-ALCL (Lymphoma) | $350,000 |
| BII Autoimmune Symptoms | $150,000 |
| Implant Rupture | $100,000 |
| Metric | Value |
|---|---|
| Allergan Recall | July 2019 |
| ALCL Cases | 1,100+ |
| MDL Registry | MDL 2921 Active |
| Layer | Audit |
|---|---|
| Allergan BioCell | +30% Scalar |
| Explant Only | 2.0x Multiplier |
| Audit Version | S-Class v2.6 |
Compensation for breast implant illness is driven by **Pathological Verification**. Our engine audits claim values based on BIA-ALCL staging, autoimmune systemic load, and the explant surgery protocols specific to textured implants.
Analysis of lymphoma cell progression
Surgical intervention value indexing
Calculates manufacturer-specific liability layers
"Calibrated against 2026 Breast Implant MDL data, FDA adverse event reports on BIA-ALCL, and surgical revision cost benchmarks."
A: BIA-ALCL is a rare type of non-Hodgkin's lymphoma that develops in the scar tissue (capsule) around breast implants, particularly those with a textured surface like Allergan's Biocell model.
A: Settlement values are heavily influenced by the specific diagnosis. In 2026, cases involving a confirmed BIA-ALCL diagnosis often see settlements ranging from $250,000 to over $500,000. Systemic illness (BII) cases typically range from $100,000 to $200,000.
A: The primary focus is on Allergan (recalled textured implants), but claims are also being filed against Mentor and Sientra. MDL 2921 consolidates breast implant products liability cases in federal court.
Don't let medical device failure go unpunished. Initiate your official S-Class forensic breast implant settlement audit.
INITIATE AUDIT NOW